High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia
暂无分享,去创建一个
S. Fröhling | K. Döhner | R. Schlenk | H. Döhner | K. Götze | A. Glasmacher | A. Benner | M. Hensel | F. Hartmann | C. Nerl | H. Salwender | W. Grimminger | A. Petzer | H. Pralle | J. Fischer | U. Germing | F. Fuentes | L. Zick | for the Gimema group | F. del Valle y Fuentes
[1] L. Escoda,et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. , 2003, Blood.
[2] D. Liang,et al. Internal tandem duplication and Asp835 mutations of the FMS‐like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia , 2003, Cancer.
[3] L. Chan,et al. Trisomy 21 and other chromosomal abnormalities in acute promyelocytic leukemia. , 2003, Cancer genetics and cytogenetics.
[4] Axel Benner,et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. , 2002, Blood.
[5] F. Mandelli,et al. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol , 2002, Leukemia.
[6] T. Ley,et al. PML/RARα and FLT3-ITD induce an APL-like disease in a mouse model , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[7] Margaret T May,et al. Regression Modelling Strategies with Applications to Linear Models, Logistic Regression, and Survival Analysis. Frank E Harrell Jr, New York: Springer 2001, pp. 568, $79.95. ISBN 0-387-95232-2. , 2002 .
[8] S. Fröhling,et al. Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] L. Degos,et al. All trans retinoic acid in acute promyelocytic leukemia , 2001, Oncogene.
[10] C. Niu,et al. Molecular cytogenetic characterization and clinical relevance of additional, complex and/or variant chromosome abnormalities in acute promyelocytic leukemia , 2001, Leukemia.
[11] Frank E. Harrell,et al. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2001 .
[12] H. Dombret,et al. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial , 2000, British journal of haematology.
[13] H. Dombret,et al. Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia , 2000, Leukemia.
[14] W. Hiddemann,et al. Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia , 2000, Leukemia.
[15] J. Miguel,et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. , 1999, Blood.
[16] T. Naoe,et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia , 1997, Leukemia.
[17] T. Barbui,et al. Molecular Remission in PML/RARα-Positive Acute Promyelocytic Leukemia by Combined All-trans Retinoic Acid and Idarubicin (AIDA) Therapy , 1997 .
[18] P. Thall,et al. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] J. Mehta,et al. Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia , 1997, British journal of haematology.
[20] S. Fröhling,et al. Design and validation of DNA probe sets for a comprehensive interphase cytogenetic analysis of acute myeloid leukemia. , 1996, Blood.
[21] Ross Ihaka,et al. Gentleman R: R: A language for data analysis and graphics , 1996 .
[22] F. Mandelli,et al. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. , 1996, Blood.
[23] R. Braziel,et al. Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. , 1995, Blood.
[24] E. Thiel,et al. Clinical aspects of acute myeloid leukemias of the FAB types M3 and M4Eo , 1993, Annals of Hematology.
[25] Zi X. Chen,et al. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. , 1991, Blood.
[26] C. Bloomfield,et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Zhen-yi Wang,et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. , 1988, Haematology and blood transfusion.
[28] E. Korn. Censoring distributions as a measure of follow-up in survival analysis. , 1986, Statistics in medicine.
[29] G Flandrin,et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.
[30] M. Halperin. Estimation in the Truncated Normal Distribution , 1952 .
[31] T. Ley,et al. PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[32] J. Esteve,et al. Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracyclin based protocol. A report of the Spanish group PETHEMA. , 2001, Haematologica.
[33] J. Esteve,et al. From bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 23, 2013. For personal use , 2000 .
[34] H. Dombret,et al. Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group. , 2000, Leukemia.
[35] J. Esteve,et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. , 1999, Blood.
[36] T. Barbui,et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. , 1997, Blood.
[37] F. Mitelman. ISCN 1995 : an international system for human cytogenetic nomenclature (1995) : recommendations of the International Standing Committee on Human Cytogenetic Nomenclature : Memphis, Tennessee, USA, October 9-13, 1994 , 1995 .
[38] E. Thiel,et al. Clinical aspects of acute myeloid leukemias of the FAB types M3 and M4Eo. The AML Cooperative Group. , 1993, Annals of hematology.
[39] R. Gray. A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .
[40] C. Bloomfield,et al. CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol , 2022 .
[41] D. Grimwade,et al. CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Presenting White Blood Cell Count and Kinetics of Molecular Remission Predict Prognosis in Acute Promyelocytic Leukemia Treated With All- Trans Retinoic Acid: Result of the Randomized MRC Trial , 2022 .
[42] D.,et al. Regression Models and Life-Tables , 2022 .